Literature DB >> 3299679

Chronic portal venous hypertension. The effect on liver blood flow and liver function and the development of esophageal varices.

L S Jensen, N Krarup, J A Larsen, C Juhl, T H Nielsen, H Dybdahl.   

Abstract

Portal venous hypertension was induced in Göttingen minipigs by banding the portal vein. The pigs were checked repeatedly during the following 24 weeks. Portal pressure increased immediately on banding, from 8.4 +/- 0.7 mm Hg to 19.4 +/- 0.7 mm Hg, and remained constant throughout the observation period. Within 5 weeks all pigs developed esophageal varices, as demonstrated by portal angiography and endoscopy. The experimentally induced portal hypertension was accompanied by a 65% decrease in hepatic blood flow, most probably caused by almost complete shunting of portal venous blood. The hepatic arterial flow appeared to be within normal limits and sufficient to cover the oxygen demand of the liver; to judge from the splanchnic elimination rate of galactose, the hemodynamic changes did not affect the functional capacity of the liver.

Entities:  

Mesh:

Year:  1987        PMID: 3299679     DOI: 10.3109/00365528708991492

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Pharmacokinetics, hepatic biotransformation and biliary and urinary excretion of bromosulfophthalein (BSP) in an experimental liver disease mimicking biliary cirrhosis.

Authors:  A Esteller; M D Torres; M Gomez-Bautista; E L Mariño; C Fernandez-Lastra; R Jimenez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

2.  Transplantation of bioengineered liver capable of extended function in a preclinical liver failure model.

Authors:  Hisanobu Higashi; Hiroshi Yagi; Kohei Kuroda; Kazuki Tajima; Hideaki Kojima; Kotaro Nishi; Toshinori Morisaku; Kazuya Hirukawa; Kazumasa Fukuda; Kentaro Matsubara; Minoru Kitago; Masahiro Shinoda; Hideaki Obara; Shungo Adachi; Kumiko Nishimura; Tohru Natsume; Masatoshi Tomi; Alejandro Soto-Gutierrez; Yuko Kitagawa
Journal:  Am J Transplant       Date:  2022-01-05       Impact factor: 8.086

3.  Systemic treatment with recombinant human epidermal growth factor accelerates healing of sclerotherapy-induced esophageal ulcers and prevents esophageal stricture formations in pigs.

Authors:  C O Juhl; L Vinter-Jensen; L S Jensen; E Nexø; J C Djurhuus; E Z Dajani
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

4.  Recombinant human epidermal growth factor prevents sclerotherapy-induced esophageal ulcer and stricture formations in pigs.

Authors:  C O Juhl; L S Jensen; T Steiniche; E Moussa
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

Review 5.  Cardiac abnormalities in liver cirrhosis.

Authors:  S S Lee
Journal:  West J Med       Date:  1989-11

6.  Chronic treatment with epidermal growth factor causes esophageal epithelial hyperplasia in pigs and rats.

Authors:  C O Juhl; L Vinter-Jensen; S S Poulsen; T F Orntoft; E Z Dajani
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

7.  Esophageal varices in rat models of liver cirrhosis.

Authors:  R Nishida; R Inoue; Y Takimoto; T Kita
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

8.  Chronic systemic treatment with epidermal growth factor in pigs causes pronounced urothelial growth with accumulation of glycoconjugates.

Authors:  L Vinter-Jensen; C O Juhl; J C Djurhuus; S S Poulsen; E Z Dajani; K D Brown; T F Orntoft; P S Teglbjaerg; E Nexø
Journal:  Am J Pathol       Date:  1995-11       Impact factor: 4.307

9.  Experimental model of portal hypertension and esophagogastric varices in minipigs: pressure and endoscopic pilot study.

Authors:  Fauze Maluf-Filho; Alberto Meyer; Pierre Pirchner Mathias Martins; Flávio Henrique Ferreira Galvão; Luiz Augusto Carneiro D'Albuquerque
Journal:  Acta Cir Bras       Date:  2022-03-07       Impact factor: 1.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.